← All stocks

Ultragenyx Pharmaceutical Inc.

RAREPharmaceuticalsLatest filing used: 2026-11-04Filings on SEC EDGAR ↗

Fast grower

Fair value per share

No filings-based value

Too few comparable years of filings.

Last close

$16.07

Nov 13, 2026

How we decide

Ten years of results

Revenue

$673M in FY2025, up 20% on the year before

FY2016: $133,000FY2017: $3MFY2018: $51MFY2019: $104MFY2020: $271MFY2021: $351MFY2022: $363MFY2023: $434MFY2024: $560MFY2025: $673M$400M$800MFY16FY19FY22FY25$673M
Show as table
YearRevenue
FY2016$133,000
FY2017$3M
FY2018$51M
FY2019$104M
FY2020$271M
FY2021$351M
FY2022$363M
FY2023$434M
FY2024$560M
FY2025$673M

Shares outstanding

Share count rose 62% over 9 years

FY2020: 61MFY2021: 68MFY2022: 70MFY2023: 74MFY2024: 90MFY2025: 99M050M100MFY16FY19FY22FY2598.6M
Show as table
YearShares outstanding
FY2016–
FY2017–
FY2018–
FY2019–
FY202061M
FY202168M
FY202270M
FY202374M
FY202490M
FY202599M

No cash earnings in the filings. No dividends paid in these years.

Delayed quote

Delayed price and chart from TradingView. This site does not receive or store these prices, and the fair value above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.

Open on Yahoo Finance ↗

Sources. Company figures: SEC EDGAR (XBRL filings), latest filing used 2026-11-04. Interest rate: U.S. Treasury, 10-year par yield, 2026-11-13. Last close: IEX Historical Data, 2026-11-13.